Effect of L-type calcium channel blocker (amlodipine) on myocardial iron deposition in patients with thalassaemia with moderate-to-severe myocardial iron deposition: protocol for a randomised, controlled trial

Amarah Shakoor, Maaman Zahoor, Alina Sadaf, Najveen Alvi, Zehra Fadoo, Arjumand Rizvi, Farheen Quadri, Fateh Ali Tipoo, Mohammad Khurshid, Zaffar Sajjad, Steven Colan, Babar S Hasan, Amarah Shakoor, Maaman Zahoor, Alina Sadaf, Najveen Alvi, Zehra Fadoo, Arjumand Rizvi, Farheen Quadri, Fateh Ali Tipoo, Mohammad Khurshid, Zaffar Sajjad, Steven Colan, Babar S Hasan

Abstract

Introduction: Sideroblastic cardiomyopathy secondary to repeated blood transfusions is a feared complication in thalassaemia. Control of myocardial iron is thus becoming the cornerstone of thalassaemia management. Recent evidence suggests a role for L-type Ca(2+) channels in mediating iron uptake by the heart. Blocking the cellular iron uptake through these channels may add to the benefit of therapy to standard chelation in reducing myocardial iron. We aim to determine the efficacy of amlodipine (a calcium channel blocker) as an adjunct to standard aggressive chelation in retarding myocardial iron deposition in thalassaemics with or without cardiomyopathy.

Outcomes: The primary outcome is to compare the efficacy of amlodipine+chelation (intervention) versus standard chelation (control) in retarding myocardial iron deposition. Secondary outcomes include the effect of amlodipine therapy on systolic and diastolic function, strain and strain rate and liver iron content.

Methods and analysis: This is a single-centre, parallel-group, prospective randomised control trial. Twenty patients will be randomised in a 1:1 allocation ratio into the intervention and control arms. In addition to conventional echocardiography, MRI T2* values for assessment of cardiac and liver iron load will be obtained at baseline and at 6 and 12 months. Cardiac T2* will be reported as the geometric mean and per cent coefficient of variation, and an increase in cardiac T2* values from baseline will be used as an end point to compare the efficacy of therapy. A p Value of <0.05 will be considered significant.

Study setting: Department of Pediatric and Child Health, Aga Khan University Hospital, Karachi, Pakistan.

Ethics and dissemination: This study has been approved by the Ethics Review Committee and Clinical Trials Unit at The Aga Khan University with respect to scientific content and compliance with applicable research and human subjects regulations. Findings will be reported through scientific publications and research conferences and project summary papers for participants.

Trial registration number: ClinicalTrials.Gov. Registration no: NCT02065492.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Figures

Figure 1
Figure 1
Adapted from Carpenter et al. This graph shows signal intensity (arbitrary units) plotted against echocardiography time (milliseconds) for the hearts shown on top. Heart 1 (with normal iron levels) has a shallow decay curve with a T2* value of >20 ms. Heart 2, owing to severe iron loading, has a much more rapid decay with T2* <10 ms.
Figure 2
Figure 2
Adapted from Carpenter et al correlated T2* values to myocardial iron content. The regression (solid line) and 95% confidence bands (dotted lines) are shown and derived from analysis of the log-log data shown in E. (A) R2* plotted versus myocardial iron concentration measured from each myocardial region of interest (ROI). (B) R2* versus myocardial iron concentration excluding heart 4. (C) Mean R2* plotted versus mean iron concentration for each heart. (D) Mean R2* versus mean iron concentration excluding heart 4. (E) ln(R2*) plotted versus ln((Fe)) for all ROIs, including heart 4, showing the best-fit linear regression line. (F) Mean midseptal R2* versus mean whole-heart R2* plotted against the line of identity showing that the septal R2* value is highly representative of the whole-heart R2*.
Figure 3
Figure 3
Sample showing ventricular strain assessment using speckle tracking. LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle.

References

    1. Khateeb B, Moatter T, Shaghil AM et al. . Genetic diversity of beta-thalassemia mutations in Pakistani population. J Pak Med Assoc 2000;50:293–6.
    1. Rahman M, Lodhi Y. Prospects and future of conservative management of beta thalassemia major in a developing country. Pak J Med Sci 2004;20:105–12.
    1. Arif F, Fayyaz J, Hamid A. Awareness among parents of children with thalassemia major. J Pak Med Assoc 2008;58:621–4.
    1. Yang T, Brittenham GM, Dong WQ et al. . Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy. J Lab Clin Med 2003;142:332–40.
    1. Yang T, Dong WQ, Kuryshev YA et al. . Bimodal cardiac dysfunction in an animal model of iron overload. J Lab Clin Med 2002;140:263–71.
    1. Wood JC, Otto-Duessel M, Gonzalez I et al. . Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl Res 2006;148:272–80.
    1. Hausse AO, Aggoun Y, Bonnet D et al. . Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 2002;87:346–9.
    1. Gujja P, Rosing DR, Tripodi DJ et al. . Iron overload cardiomyopathy: better understanding of an increasing disorder. J Am Coll Cardiol 2010;56:1001–12.
    1. Aessopos A, Farmakis D, Deftereos S et al. . Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest 2005;127:1523–30.
    1. Borgna-Pignatti C, Cappellini MD, De Stefano P et al. . Survival and complications in thalassemia. Ann N Y Acad Sci 2005;1054:40–7.
    1. Olivieri NF, Nathan DG, MacMillan JH et al. . Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994;331:574–8.
    1. Chern JP, Su S, Lin KH et al. . Survival, mortality, and complications in patients with beta-thalassemia major in northern Taiwan. Pediatr Blood Cancer 2007;48:550–4.
    1. Chattipakorn N, Kumfu S, Fucharoen S et al. . Calcium channels and iron uptake into the heart. World J Cardiol 2011;3:215–18.
    1. Oudit GY, Trivieri MG, Khaper N et al. . Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med (Berl) 2006;84:349–64.
    1. Tsushima RG, Wickenden AD, Bouchard RA et al. . Modulation of iron uptake in heart by L-type Ca2+ channel modifiers: possible implications in iron overload. Circ Res 1999;84:1302–9.
    1. Oudit GY, Sun H, Trivieri MG et al. . L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 2003;9:1187–94.
    1. Brittenham GM, Griffith PM, Nienhuis AW et al. . Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567–3.
    1. Olivieri NF. The beta-thalassemias. N Engl J Med 1999;341: 99–109.
    1. Pennell DJ, Porter JB, Cappellini MD et al. . Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood 2010;115:2364–71.
    1. Pennell DJ, Porter JB, Cappellini MD et al. . Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with beta-thalassemia major. Haematologica 2012;97: 842–8.
    1. Pennell DJ, Porter JB, Cappellini MD et al. . Continued improvement in myocardial T2* over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload. Haematologica 2011;96:48–54.
    1. Pepe A, Meloni A, Rossi G et al. . Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy. J Cardiovasc Magn Reson 2013;15:1.
    1. Maggio A, Filosa A, Vitrano A et al. . Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells Mol Dis 2011;47:166–75.
    1. Tanner MA, Galanello R, Dessi C et al. . A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007;115:1876–84.
    1. Veríssimo MP, Loggetto SR, Fabron Junior A et al. . Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion. Rev Bras Hematol Hemoter 2013;35:428–34.
    1. Westwood M, Anderson LJ, Firmin DN et al. . A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 2003;18:33–9.
    1. Anderson LJ, Holden S, Davis B et al. . Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171–9.
    1. Khouri SJ, Maly GT, Suh DD et al. . A practical approach to the echocardiographic evaluation of diastolic function. J Am Soc Echocardiogr 2004;17:290–7.
    1. Fernandes JL, Sampaio EF, Fertrin K et al. . Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial. Am J Med 2013;126:834–7.
    1. Sauerbrey-Wullkopf N, Kupper W. [Amlodipine versus nifedipine retard. A randomized double-blind comparative study on long-term efficacy and safety of amlodipine and nifedipine retard in the monotherapy of chronic stable angina pectoris]. Herz 2001;26:149–56.
    1. Buck ML. Amlodipine use in pediatric hypertension. Pediatr Pharmacother July 2003;9:7.
    1. Mavrogeni S, Pepe A, Lombardi M. Evaluation of myocardial iron overload using cardiovascular magnetic resonance imaging. Hellenic J Cardiol 2011;52:385–90.
    1. Westwood MA Anderson LJ, Maceira AM et al. . Normalized left ventricular volumes and function in thalassaemia major patients with normal myocardial iron. J Magn Reson Imaging 2007;25:1147–51.
    1. He T, Gatehouse PD, Kirk P et al. . Myocardial T*2 measurement in iron-overloaded thalassemia: an ex vivo study to investigate optimal methods of quantification. Magn Reson Med 2008;60:350–6.
    1. Bonny JM, Zanca M, Boire JY et al. . T2 maximum likelihood estimation from multiple spin-echo magnitude images. Magn Reson Med 1996;36:287–93.
    1. Carpenter JP, He T, Kirk P et al. . On T2* magnetic resonance and cardiac iron. Circulation 2011;123:1519–28.
    1. Wyatt HL, Meerbaum S, Heng MK et al. . Cross-sectional echocardiography. III. Analysis of mathematic models for quantifying volume of symmetric and asymmetric left ventricles. Am Heart J 1980;100(6 Pt 1):821–8.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa